SLC5A2 and diabetes mellitus: Balazki et al. first integrated the model of diabetes-associated renal hyperfiltration and PBPK model of dapagliflozin to confirm co-administration of renal SGLT1 inhibition is effective for reversing hyperfiltration compared to SGLT2 inhibition alone (Balazki et al., 2018).